Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine in CDKL5 Deficiency Disorder
NCT03861871Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fenfluramine in CDKL5 deficiency disorder (CDD), sponsored by NYU Langone Health. Started Oct 2019; status: completed.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NCT03861871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861871.